In a groundbreaking initiative set to revolutionize cancer diagnosis, Metropolis Healthcare Limited has entered into a strategic partnership with QritiveTM, a leading AI solutions provider based in Singapore. This collaboration aims to redefine cancer care by incorporating state-of-the-art AI technology into pathology workflows.
Enhancing Diagnostic Precision and Efficiency
Metropolis Healthcare, a pioneer in diagnostic services in India, has consistently demonstrated a commitment to delivering precise and timely diagnoses. The integration of Qritive’s advanced AI platform, including the PantheonTM image management system, is poised to further enhance diagnostic accuracy and efficiency. This strategic move aims to streamline cancer diagnosis processes, improve quality control, and significantly reduce turnaround times.
Mr. Surendran Chemmenkottil, CEO of Metropolis Healthcare Limited, emphasized the critical role of AI in modern healthcare. “AI insights have the potential to expedite the diagnosis of various cancers, supporting pathologists and clinicians in making more effective treatment decisions,” he stated. This integration promises to elevate the standard of care and improve patient outcomes by providing faster and more accurate diagnoses.
Commitment to Personalized Cancer Diagnosis
Dr. Kirti Chadha, Chief Scientific Officer and Senior Oncopathologist at Metropolis Healthcare highlighted the organization’s dedication to delivering personalized cancer diagnoses. “The integration of advanced AI technology empowers our pathologists to deliver highly accurate results, swiftly prioritize urgent cases, and enhance overall diagnostic quality through AI-generated insights,” Dr. Chadha noted. This approach ensures that each patient receives a tailored diagnosis, which is crucial for effective treatment planning.
Proven Clinical Benefits of AI Integration
Clinical studies conducted by Qritive have demonstrated significant benefits from the use of AI in pathology. These studies show remarkable reductions in diagnosis time and discordance among pathologists, leading to heightened diagnostic accuracy and improved patient outcomes.
Mr. Bruno Occhipinti, CEO of Qritive, expressed pride in collaborating with Metropolis Healthcare. “This partnership highlights the transformative potential of AI in closing the gap in cancer care, improving health outcomes, and supporting clinicians in delivering quality care,” he said.
Setting a New Standard in Cancer Diagnostics
As a leading developer of AI solutions, Qritive continues to push the boundaries of digital pathology for cancer diagnosis. Their AI-based solutions are designed to support clinicians in providing the highest quality care, leveraging advanced technology to improve health outcomes. The partnership between Metropolis Healthcare and Qritive marks a significant milestone in the integration of AI technology into pathology workflows.
This collaboration sets a new standard in cancer diagnostics and reaffirms both organizations’ commitment to excellence in healthcare. Through this innovative approach, Metropolis Healthcare and Qritive are poised to transform the landscape of cancer care, offering hope for more effective and timely treatments for patients worldwide.
To read more startup stories visit- thesingaporepress